Overview
Maude Lagace-Dumont practices practicing medicine in Montreal, Canada.
Ms. Lagace-Dumont is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Febrile Neutropenia and Graft Versus Host Disease (GvHD).
She is actively involved in clinical research, co-authoring 17 peer reviewed articles.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Maude Lagace-Dumont
Is Maude Lagace-Dumont a top-rated expert for Febrile Neutropenia?
MediFind is an objective health platform that identifies experts based on real-world data. Maude Lagace-Dumont is classified as an Advanced expert for Febrile Neutropenia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Maude Lagace-Dumont participate in research or clinical trials?
Yes. Maude Lagace-Dumont has published 17 articles and abstracts on conditions like Febrile Neutropenia. You can view a list of Maude Lagace-Dumont's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- Febrile NeutropeniaMs. Lagace-Dumont isAdvanced. Learn about Febrile Neutropenia.
- Experienced
- Graft Versus Host Disease (GvHD)Ms. Lagace-Dumont isExperienced. Learn about Graft Versus Host Disease (GvHD).